A. Luca

发表

The prognostic value to predict virological outcomes of 14 distinct systems used to interpret the results of genotypic HIV-1 drug resistance testing in untreated patients starting their first HAART

C. Perno, A. Lepri, C. Balotta, 2004 .

Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations initiating therapy : modelling study and economic analysis

D. Pillay, A. Phillips, J. Lundgren, 2018 .

Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study

A. d’Arminio Monforte, G. Ippolito, A. Antinori, 2001, Journal of NeuroVirology.

Aerosolized pentamidine, cotrimoxazole and dapsone‐pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis

A. Antinori, A. Cingolani, G. Scoppettuolo, 1995, AIDS.

UvA-DARE (Digital Academic Repository) Combining epidemiological and genetic networks signifies the importance of early treatment in HIV-1 transmission

P. Sloot, Narges Zarrabi, R. Belleman, 2012 .

Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy

A. d’Arminio Monforte, A. Lazzarin, M. Clerici, 2009, Infection.

Hyperbilirubinemia during Atazanavir Treatment in 2,404 Patients in the Italian Atazanavir Expanded Access Program and MASTER Cohorts

R. Maserati, A. Lazzarin, A. Antinori, 2009, Infection.

Evaluation of cerebrospinal fluid EBV‐DNA and IL‐10 as markers for in vivo diagnosis of AIDS‐related primary central nervous system lymphoma

L. Larocca, M. Scerrati, A. Antinori, 1995, British journal of haematology.

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

A. Gasbarrini, R. Bruno, G. Filice, 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems

F. Chiodo, A. Monforte, C. Perno, 2004, Antiviral therapy.

Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis

M. Colafigli, P. Navarra, A. Luca, 2014, Infection.

Patient-reported nonadherence to HAART is related to protease inhibitor levels.

A. Wu, A. Antinori, D. Jacobson, 2000 .

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort

R. Paredes, A. Vandamme, P. Sloot, 2013, BMC Infectious Diseases.

Three-Year Clinical Outcomes of Resistance Genotyping and Expert Advice: Extended follow-up of the Argenta Trial

A. Cingolani, A. Ammassari, A. Luca, 2005, Antiviral therapy.

AVT-923 De Luca

A. Cingolani, A. Ammassari, A. Luca, 2006 .

Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis

G. Fadda, A. Cingolani, M. Sanguinetti, 2011, Journal of NeuroVirology.

Haemopoietic CD34+ progenitor cells are not infected by HIV‐1 in vivo but show impaired clonogenesis

G. Leone, A. Antinori, E. Tamburrini, 1993, British journal of haematology.

Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy

L. Pagano, G. Leone, P. Cattani, 2010, Bone Marrow Transplantation.

Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from an Inter-Cohort Analysis

B. Ledergerber, J. Lundgren, F. Dabis, 2006, Antiviral therapy.

Original article Predicting the magnitude of short-term CD4 + T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy

E. Seminari, A. Lazzarin, A. Antinori, 2010 .

Detection of Pneumocystis carinii DNA in HIV Patients with P. carinii pneumonia (PCP) and in Animal Models

M. Zolfo, E. Dei‐Cas, E. Tamburrini, 1996, The Journal of eukaryotic microbiology.

Comparison of Two PCR Methods for Detection of Pneumocystis carinii in Bronchoalveolar Lavage Fluid

M. Zolfo, E. Tamburrini, A. Luca, 1996, The Journal of eukaryotic microbiology.

Construction, Training and Clinical Validation of An Interpretation System for Genotypic HIV-1 Drug Resistance Based on Fuzzy Rules Revised by Virological Outcomes

Marilena Vendittelli, Giovanni Ulivi, Francesco Baldini, 2003, Antiviral therapy.

Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis

B. Ledergerber, J. Lundgren, F. Dabis, 2005, Antiviral Therapy.

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients

M. Moroni, G. Filice, P. Narciso, 2000, AIDS.

Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone

A. d’Arminio Monforte, C. Mussini, P. Cicconi, 2007, Infection.

Hepatitis B virus surface antigen seroconversion after pegylated interferon-alpha treatment in an HIV-infected individual with chronic hepatitis B

A. Luca, B. Rossetti, C. Bianco, 2012, Infection.

L. Larocca, A. Antinori, A. Cingolani, 1999 .

Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patients

A. Antinori, A. Cingolani, R. Murri, 1999, The Lancet.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Virological response to Salvage Therapy in HIV-Infected Persons Carrying the Reverse Transcriptase K65R Mutation

F. Ceccherini‐Silberstein, A. Antinori, P. Lorenzini, 2007, Antiviral therapy.

Simplification to atazanavir/ritonavir plus lamivudine versus maintaining atazanavir/ritonavir+2NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trial

G. d’Ettorre, A. Antinori, M. Colafigli, 2016 .

Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals

A. Luca, 2002 .

L. Larocca, A. Cingolani, P. Pezzotti, 2000 .

Patient‐Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels

A. Wu, A. Antinori, D. Jacobson, 2000, Journal of acquired immune deficiency syndromes.

Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia

A. Antinori, E. Tamburrini, R. Murri, 1992, The Lancet.

HIV tropism and its relationship with transmitted resistance in naive patients

A. Antinori, M. Zazzi, D. Francisci, 2013 .

OP-JANM180350 1..11

F. Ceccherini‐Silberstein, M. Capobianchi, A. Antinori, 2018 .

HIV-1 Non-R 5 Co-receptor Tropism is Associated with a Larger Size of the Viral Reservoir but not with a Higher Risk of Virological Rebound in Patients on Effective Antiretroviral Therapy

A. Luca, S. Giambenedetto, M. Fabbiani, 2015 .

Patient-reported and physician-estimated adherence to HAART

Albert W. Wu, Rita Murri, A. Wu, 2004, Journal of General Internal Medicine.

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

et al., Andrea De Luca, Mattia C. F. Prosperi, 2011, BMC Medical Informatics Decis. Mak..

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program

R. Bruno, V. Vullo, A. Antinori, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pneumocystis carinii stimulates in vitro production of tumor necrosis factor-α by human macrophages

A. Antinori, E. Tamburrini, A. Luca, 2004, Medical Microbiology and Immunology.

Epstein-Barr V irus I nfection I s P redictive o f C NS Involvement i n S ystemic A IDS-Related N on-Hodgkin's Lymphomas

L. Larocca, E. Pescarmona, G. Gaidano, 2000 .

Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy

M. Zazzi, D. Francisci, S. Di Giambenedetto, 2008, Antiviral therapy.

Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era

G. Ippolito, A. Antinori, A. Cingolani, 2011, Journal of NeuroVirology.

Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy.

G. Ippolito, A. Antinori, A. Cingolani, 2001 .

Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy

A. Antinori, A. Cingolani, A. Ammassari, 2005, Journal of NeuroVirology.

OAEM_A_178544 147..159

A. Luca, M. Mariani, M. Riccardi, 2019 .

Discontinuation of Primary Prophylaxis for Pneumocystis carinii Pneumonia and Toxoplasmic Encephalitis in Human Immunodeﬁciency Virus Type I– Infected Patients: The Changes in Opportunistic Prophylaxis Study for the Changes in Opportunistic Prophylaxis (CIOP)

M. Moroni, F. Chiodo, A. Antinori, 2022 .

Combining social and genetic networks to study HIV transmission in mixing risk groups

Andrea De Luca, Peter M. A. Sloot, Narges Zarrabi, 2013 .

Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy.

C. Mussini, A. Cossarizza, M. Nasi, 2012 .

Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA)

A. Antinori, P. Cinque, P. Lorenzini, 2011, Journal of NeuroVirology.

Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization

Giovanni Ulivi, Andrea De Luca, Mattia C. F. Prosperi, 2009, Bioinform..

Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy

C. Yiannoutsos, A. Luca, 2001, Journal of NeuroVirology.

'Buffalo hump' in HIV-1 infection (multiple letters) [4]

A. Antinori, K. Fattinger, R. Murri, 1998 .

Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure

G. Fadda, P. Cattani, P. Navarra, 2011, Infection.

Evolution of Antiretroviral Prescription and Response over a Period of 8 years: an Italian Multicentre Observational Prospective Cohort Study

C. Tinelli, C. Torti, G. Carosi, 2008, Infection.

Resistance to newly approved and investigational protease inhibitors.

A. Luca, 2007 .

Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison

A. Antinori, A. Monforte, P. Cicconi, 2005, Antiviral therapy.

TABLE 1. Predictors of Atherogenic Lipid Profile According to NCEP Thresholds (Results From Separate Multivariate Logistic Regression Models)

A. Cingolani, E. Tamburrini, F. Baldini, 2004 .

Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: Predictors of virological response and drug resistance evolution in a multi-cohort study

M. Prosperi, M. Zazzi, P. Cicconi, 2009, Infection.

Phenotypic profile and change in cerebrospinal fluid EBV-DNA burden during therapy as prognostic factors in AIDS-related primary central nervous system lymphoma

L. Larocca, G. Gaidano, A. Antinori, 1998 .

Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection

G. Fadda, M. Prosperi, M. Sali, 2011, European Journal of Clinical Microbiology & Infectious Diseases.

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program.

R. Bruno, V. Vullo, A. Antinori, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Erratum: Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma (British Journal of Haematology, 90, 844-849, (1995))

L. Larocca, M. Scerrati, A. Antinori, 1995 .

Role of HCV viraemia and HCV genotype in the immune recovery from HAART in a cohort of antiretroviral naïve HIV-infected individuals

G. Ippolito, M. Capobianchi, F. Carletti, 2005 .

Improved detection of JC virus DNA in cerebrospinal fluid for diagnosis of AIDS-related progressive multifocal leukoencephalopathy

A. Antinori, A. De Luca, A. Cingolani, 1996, Journal of clinical microbiology.

Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients

G. D’Amico, A. Morabito, M. Traina, 2014, Alimentary pharmacology & therapeutics.

Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma.

L. Larocca, M. Scerrati, A. Antinori, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV‐1 positive patients with well‐estimated dates of seroconversion

C. Morrison, P. Vanhems, A. Kamali, 2017, HIV medicine.

PCR detection of Toxoplasma gondii DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions.

A. De Luca, A. Cingolani, R. Murri, 1996, Journal of medical microbiology.

Detection of T.gundii‐DNA by PCR in AIDS‐related toxoplasmic encephalitis.

A. Antinori, A. Cingolani, R. Murri, 1996, The Journal of eukaryotic microbiology.

Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma.

L. Larocca, M. Scerrati, A. Antinori, 1998, Journal of the National Cancer Institute.

Serological response to hepatitis B virus vaccine in HIV‐infected children in Tanzania

A. De Luca, E. Montomoli, A. Luca, 2008, HIV medicine.

The global spread of HIV-1 subtype B epidemic

M. Poljak, A. Wensing, R. Paredes, 2016 .

Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).

M. Moroni, G. Filice, R. Maserati, 2006, The Journal of antimicrobial chemotherapy.

Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas.

L. Larocca, E. Pescarmona, G. Gaidano, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European guidelines on the clinical management of HIV-1 tropism testing.

A. Wensing, H. Walter, R. Kaiser, 2011, The Lancet. Infectious diseases.

First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Lazzarin, 2018, HIV medicine.

Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Cardiovascular risk score change in HIV‐1‐infected patients switched to an atazanavir‐based combination antiretroviral regimen

M. Colafigli, A. De Luca, E. Tamburrini, 2008, HIV medicine.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Response to pegylated interferon plus ribavirin in HIV‐infected patients with chronic hepatitis C due to genotype 4

R. Bruno, V. Soriano, A. De Luca, 2008, Journal of viral hepatitis.

Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy.

A. Antinori, A. De Luca, A. Cingolani, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.

R. Maserati, M. Zazzi, M. Colafigli, 2009, The Journal of antimicrobial chemotherapy.

Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe.

A. Wensing, R. Paredes, R. Kaiser, 2015, The Journal of antimicrobial chemotherapy.

Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009.

M. Prosperi, M. Zazzi, S. Paolucci, 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure.

M. Colafigli, A. Cingolani, A. Luca, 2008, AIDS research and human retroviruses.

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

A. Gasbarrini, R. Bruno, G. Filice, 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. I.CO.N.A. Study Group.

M. Moroni, G. Ippolito, A. Phillips, 2000 .

Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.

M. Moroni, A. d’Arminio Monforte, A. Antinori, 2000, The Journal of infectious diseases.

Application of molecular methods for detection and transmission analysis of mycobacterium tuberculosis drug resistance in patients attending a reference hospital in Italy.

G. Fadda, A. Antinori, A. De Luca, 1999, The Journal of infectious diseases.

Evaluation of glomerular filtration rate in HIV‐1‐infected patients before and after combined antiretroviral therapy exposure *

Colangeli, A. Lepri, A. Gori, 2011, HIV medicine.

Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.

M. Moroni, R. Bruno, A. Antinori, 2001 .

Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study

A. d’Arminio Monforte, G. Ippolito, A. Antinori, 2001, Journal of NeuroVirology.

Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.

A. Antinori, V. Tozzi, A. Cingolani, 2000, AIDS.

Changing disease patterns in focal brain lesion-causing disorders in AIDS.

A. Antinori, A. Cingolani, P. Pezzotti, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

PLOS ONE HIV-1 A1 subtype epidemic in Italy originated from Africa and Eastern Europe and shows a high frequency of transmission chains involving intravenous drug users

M. Zazzi, M. Ciccozzi, --Manuscript Draft, 2015 .

Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients

A. Antinori, C. Mussini, J. Fehr, 2016 .

HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir

A. De Luca, M. Zazzi, B. Clotet, 2012, Antimicrobial Agents and Chemotherapy.